AstraZeneca’s MedImmune unit has announced a joint venture (JV) with WuXi AppTec, to develop and market the experimental biological drug MEDI5117 in China. MEDI5117 is a fully human monoclonal ...
Big drugmakers such as AstraZeneca, meanwhile, are working to create separate supply chains for China and the West. Amicus ...
AstraZeneca has confirmed that some of its ... and R&D centre in Shanghai and a network of supply sites in Wuxi, Taizhou, and Qingdao, employing around 16,000 people. China has expanded rapidly ...
Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback